Heidi Guthrie, Natalia Castro, Carine Beysen, Linda Morrow and Marcus Hompesch
Poster presented at the NASH-TAG Conference, Park City, UT, Jan 3-5, 2019.
- The use of paired liver biopsies in early phase NAFLD/NASH trials is not pragmatic due to the short nature of these studies.
- MRI-PDFF is well correlated with histology‐determined steatosis in patients with NAFLD and is often used as a surrogate non-invasive biomarker of hepatic steatosis in NAFLD/NASH clinical trials.
- There is, however, a need for an optimal screening strategy due to cost and timeline implications of subjects failing to meet MRI-PDFF inclusion criteria.
- The assessment of CAP is easy to perform and inexpensive relative to MRI-PDFF and is currently used as a screening tool to pre-identify subjects with NAFLD.